Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression

International Clinical Psychopharmacology

Volumn 13, Issue 2, 1998, Pages 83-86

  Fischer, P ^a   Tauscher, J ^a   Kufferle B ^a   Kasper, S ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Augmentation; Buspirone; Refractory depression; Serotonin selective re uptake inhibitors

Indexed keywords

BUSPIRONE; CITALOPRAM; FLUOXETINE; MAPROTILINE; MIRTAZAPINE; PAROXETINE; SEROTONIN AGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG POTENTIATION; FEMALE; HUMAN; MALE; PATIENT SELECTION; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM;

EID: 0031970708     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199803000-00005     Document Type: Article

References (13)

1. Bakish D (1991). Fluoxetine potentiation by buspirone: three case histories. Can J Psychiatry 36:749-750.
2. Easterhrook PJ, Berlin JA, Gopalan R, Matthews D (1991). Publication bias in clinical research. Lancet 337:876-872.
3. Fabre LP (1990). Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatry 51 (Suppl. a):55-56.
4. Gammans RE, Stringfellow JC, Hvizdos AJ, Seidehamel RJ, Cohn JB, Wilcox CS et al. (1992). Use of buspirone in patients with generalized anxiety disorder and coexisting depressive symptoms. A meta-analysis of eight randomized, controlled studies. Neuropsychobiology 25:193-201.
5. Harvey KV, Balon R (1995). Augmentation with buspirone: a review. Ann Clin Psychiatry 7:143-147.
6. Jacobson FM (1991). Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 52:217-220.
7. Joffe RT, Levitt AJ, Sokolov STM (1996). Augmentation strategies: focus on anxiolytics. J Clin Psychiatry 57 (Suppl. 7):25-31.
8. Joffe RT, Schuller DR (1993). An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 54:269-271.
9. Kasper S (1997). Vorgehen bei Therapieresistenz depressiver Störungen - die Rolle von Buspiron. In: Buspiron, ein Anxiolytikum. Pharmakologische und klinische Aspekte (F Kulhanek, GAE Rudolf, eds). Deutscher Universitätsverlag, Wiesbaden.
10. Keller MB, Klerman GL, Lavori PW, Coryell W, Endicott J, Taylor J (1984). Long-term outcome of episodes of major depression. JAMA 252:788-792.
11. Robinson DS, Alms DR, Andary JJ, Messina ME (1990). Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 10 (Suppl. 3):67S-76S.
12. Thase ME, Rush AJ (1995). Chapter 92: Treatment-resistant depression. In: Psychopharmacology: the Fourth Generation of Progress (FE Bloom, DJ Kupfer, eds), New York: Raven Press. pp. 1081-1097.
13. Thase ME, Kupfer DJ (1987). Characteristics of treatment-resistant depression. In: Treating resistant depression (J Zohar, RH Belmaker, eds), New York: PMA Publishing. pp. 23-45.